FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304844> ?p ?o ?g. }

• W4367304844 abstract "<h3>Objective:</h3> To assess changes in the proportion of patients who converted to a positive anti-JC virus (JCV) antibody (Ab) serostatus before and during the COVID-19 pandemic. <h3>Background:</h3> Natalizumab, approved to treat relapsing MS, is associated with increased risk of progressive multifocal leukoencephalopathy, a rare opportunistic infection of the brain due to JCV. Masking and social distancing in the US during the COVID-19 pandemic profoundly attenuated the spread of seasonal influenza in 2020–2021. The mode of JCV transmission is not well defined, thus the pandemic offered a unique epidemiological opportunity to evaluate if isolation and masking during the COVID-19 pandemic affected JCV transmission. <h3>Design/Methods:</h3> Data from the TOUCH database for 22,375 patients treated with natalizumab in the US from 2017–2022 with available anti-JCV Ab record was assessed in annual epochs from April 1 to March 31. Anti-JCV Ab serostatus was determined by STRATIFY JCV^® DxSELECT. US regions examined (Northeast/South/Central/West) were determined using infusion site ZIP codes. <h3>Results:</h3> From April 1, 2017 to March 31, 2018, anti-JCV Ab serostatus change was observed for 7.7% of patients, with serostatus change of 7.4% and 7.4% of patients in the following 2 years (2018–2019 and 2019–2020). During the first and second years of the COVID-19 pandemic (2020–2021 and 2021–2022), 7.3% and 7.2% of patients’ serostatus changed, respectively. There were no differences in serostatus change by US region. Multivariate predictors of JC seroconversion will be shown when presented. <h3>Conclusions:</h3> The proportion of natalizumab patients with anti-JCV Ab serostatus change did not significantly differ during the first 2 years of the COVID-19 pandemic compared with the 3 prior years. These results suggest that, in contrast to seasonal influenza, masking and social distancing had no discernable effect on JCV serostatus changes. If not spread through social contact, further studies are needed to understand how JCV is transmitted. <b>Disclosure:</b> Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Krieger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Krieger has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Expert Witness. The institution of Dr. Krieger has received research support from Novartis. The institution of Dr. Krieger has received research support from Bristol Myers Squibb. Mrs. Sinks has received personal compensation for serving as an employee of Biogen . Dr. Huang has nothing to disclose. Ms. Wen has a non-compensated relationship as a Statistician with Biogen that is relevant to AAN interests or activities. Mrs. Steverson has received personal compensation for serving as an employee of Biogen. Mrs. Steverson has stock in Biogen. An immediate family member of Dr. Piccinini has received personal compensation for serving as an employee of Biogen. Dr. Piccinini has received stock or an ownership interest from Biogen. Dr. Kalina has received personal compensation for serving as an employee of Biogen. Dr. White has stock in Biogen. Mrs. Avila has received personal compensation for serving as an employee of Biogen. Mrs. Avila has stock in Biogen." @default.
• W4367304844 created "2023-04-29" @default.
• W4367304844 creator A5036128004 @default.
• W4367304844 creator A5060948514 @default.
• W4367304844 creator A5065230684 @default.
• W4367304844 creator A5075953942 @default.
• W4367304844 creator A5082246505 @default.
• W4367304844 creator A5086655951 @default.
• W4367304844 creator A5088037348 @default.
• W4367304844 creator A5091135797 @default.
• W4367304844 creator A5001549810 @default.
• W4367304844 date "2023-04-25" @default.
• W4367304844 modified "2023-09-24" @default.
• W4367304844 title "Anti-JC Virus Serostatus Changes Before and During the COVID-19 Pandemic in US Patients with Multiple Sclerosis (MS) Treated with Natalizumab (P12-3.007)" @default.
• W4367304844 doi "https://doi.org/10.1212/wnl.0000000000202884" @default.
• W4367304844 hasPublicationYear "2023" @default.
• W4367304844 type Work @default.
• W4367304844 citedByCount "0" @default.
• W4367304844 crossrefType "proceedings-article" @default.
• W4367304844 hasAuthorship W4367304844A5001549810 @default.
• W4367304844 hasAuthorship W4367304844A5036128004 @default.
• W4367304844 hasAuthorship W4367304844A5060948514 @default.
• W4367304844 hasAuthorship W4367304844A5065230684 @default.
• W4367304844 hasAuthorship W4367304844A5075953942 @default.
• W4367304844 hasAuthorship W4367304844A5082246505 @default.
• W4367304844 hasAuthorship W4367304844A5086655951 @default.
• W4367304844 hasAuthorship W4367304844A5088037348 @default.
• W4367304844 hasAuthorship W4367304844A5091135797 @default.
• W4367304844 hasConcept C107130276 @default.
• W4367304844 hasConcept C119599485 @default.
• W4367304844 hasConcept C126322002 @default.
• W4367304844 hasConcept C127413603 @default.
• W4367304844 hasConcept C142462285 @default.
• W4367304844 hasConcept C159047783 @default.
• W4367304844 hasConcept C203014093 @default.
• W4367304844 hasConcept C2522874641 @default.
• W4367304844 hasConcept C2776535787 @default.
• W4367304844 hasConcept C2779134260 @default.
• W4367304844 hasConcept C2779150272 @default.
• W4367304844 hasConcept C2780640218 @default.
• W4367304844 hasConcept C2780644213 @default.
• W4367304844 hasConcept C2781004633 @default.
• W4367304844 hasConcept C3008058167 @default.
• W4367304844 hasConcept C524204448 @default.
• W4367304844 hasConcept C71924100 @default.
• W4367304844 hasConcept C761482 @default.
• W4367304844 hasConcept C89623803 @default.
• W4367304844 hasConceptScore W4367304844C107130276 @default.
• W4367304844 hasConceptScore W4367304844C119599485 @default.
• W4367304844 hasConceptScore W4367304844C126322002 @default.
• W4367304844 hasConceptScore W4367304844C127413603 @default.
• W4367304844 hasConceptScore W4367304844C142462285 @default.
• W4367304844 hasConceptScore W4367304844C159047783 @default.
• W4367304844 hasConceptScore W4367304844C203014093 @default.
• W4367304844 hasConceptScore W4367304844C2522874641 @default.
• W4367304844 hasConceptScore W4367304844C2776535787 @default.
• W4367304844 hasConceptScore W4367304844C2779134260 @default.
• W4367304844 hasConceptScore W4367304844C2779150272 @default.
• W4367304844 hasConceptScore W4367304844C2780640218 @default.
• W4367304844 hasConceptScore W4367304844C2780644213 @default.
• W4367304844 hasConceptScore W4367304844C2781004633 @default.
• W4367304844 hasConceptScore W4367304844C3008058167 @default.
• W4367304844 hasConceptScore W4367304844C524204448 @default.
• W4367304844 hasConceptScore W4367304844C71924100 @default.
• W4367304844 hasConceptScore W4367304844C761482 @default.
• W4367304844 hasConceptScore W4367304844C89623803 @default.
• W4367304844 hasLocation W43673048441 @default.
• W4367304844 hasOpenAccess W4367304844 @default.
• W4367304844 hasPrimaryLocation W43673048441 @default.
• W4367304844 hasRelatedWork W2019110331 @default.
• W4367304844 hasRelatedWork W2020670698 @default.
• W4367304844 hasRelatedWork W2039705148 @default.
• W4367304844 hasRelatedWork W2050997486 @default.
• W4367304844 hasRelatedWork W2055420112 @default.
• W4367304844 hasRelatedWork W2144493921 @default.
• W4367304844 hasRelatedWork W2157553990 @default.
• W4367304844 hasRelatedWork W2256837158 @default.
• W4367304844 hasRelatedWork W2410288657 @default.
• W4367304844 hasRelatedWork W4206515691 @default.
• W4367304844 isParatext "false" @default.
• W4367304844 isRetracted "false" @default.
• W4367304844 workType "article" @default.